Key Takeaways:
Two law firms have filed class-action lawsuits against Aquestive Therapeutics Inc. (NASDAQ: AQST), alleging the company and its officers made materially false and misleading statements regarding the approval prospects for its key drug candidate, Anaphylm.
The lawsuits, filed by Bronstein, Gewirtz & Grossman, LLC and The Rosen Law Firm, seek to recover damages for investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026. The firms allege that investors suffered damages due to the company's alleged misrepresentations.
According to the complaints, Aquestive overstated the timeline for approval of its New Drug Application (NDA) for Anaphylm, a sublingual film for anaphylaxis. The lawsuits claim the company concealed or minimized significant risks related to "human factors" associated with the product's use, including its packaging, administration, and labeling, which ultimately impacted the likelihood of regulatory approval.
"The Complaint alleges that, throughout the relevant period, Defendants made materially false and misleading statements and/or failed to disclose that the timeline for approval and launch of Aquestive's New Drug Application for Anaphylm was materially overstated," Bronstein, Gewirtz & Grossman stated in a press release.
The legal actions create significant uncertainty for Aquestive, potentially leading to financial penalties and a loss of investor confidence. The lead plaintiff deadline for investors to move the court is May 4, 2026. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.
The core of the allegations focuses on the company's failure to disclose the full extent of challenges in the Anaphylm NDA submission. While the company expressed confidence in a timely approval by the Prescription Drug User Fee Act (PDUFA) date of January 31, 2026, the lawsuits argue these statements lacked a reasonable basis due to the known human-factors issues.
Both law firms are encouraging eligible investors to come forward. The filings underscore the legal risks companies face when communicating progress on drug development pipelines, particularly concerning interactions with regulatory bodies like the FDA.
The lawsuits signal that the company's previous assurances about Anaphylm's path to market may have been incomplete. Investors will now watch for the court's decision on class certification and the appointment of a lead plaintiff by the May 4, 2026 deadline.
This article is for informational purposes only and does not constitute investment advice.
